Teva announces launch of generic Avapro® and generic Avalide® in the United States
2 April 2012 | By Teva Pharmaceutical Industries Ltd
180-day period of marketing exclusivity awarded...
List view / Grid view
2 April 2012 | By Teva Pharmaceutical Industries Ltd
180-day period of marketing exclusivity awarded...
2 April 2012 | By Novartis
QVA149 efficacy, safety and exercise endurance primary endpoints all met[1],[2],[3]...
2 April 2012 | By GlaxoSmithKline
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
2 April 2012 | By Merck
Merck announced that data from the pivotal Phase III study with ZOSTAVAX® in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases...
2 April 2012 | By Amgen
Collaboration comprises five monoclonal antibodies brodalumab (AMG 827) Phase 3 trial planned in 2012...
2 April 2012 | By Merial
Merial, the Animal Health division of Sanofi, announced that it has acquired Newport Laboratories...
2 April 2012 | By Eli Lilly and Company
Studies provided basis for ongoing Phase I, II studies in gastric, other cancers...
30 March 2012 | By Catalent Pharma Solutions
Cornell Stamoran, Catalent Pharma Solutions will be a guest panelist at New Jersey’s PharmFest 2012...
30 March 2012 | By Gerresheimer AG
Gerresheimer Medical Plastic Systems continues to expand its range of services in order to meet customer demand...
30 March 2012 | By Roche
Roche have announced topline results of EMILIA...
30 March 2012 | By Abbott
New PLEX-ID system and three clinical tests introduced in the European Union...
29 March 2012 | By H. Lundbeck A/S
The Board of Directors of H. Lundbeck A/S has resolved, pursuant to the authorisation in article 4.4 of the company's articles...
29 March 2012 | By I Holland Ltd
I Holland are delighted to announce the launch of a two year TSAR project...
29 March 2012 | By BASF
BASF is setting itself ambitious goals...
29 March 2012 | By Roche
Roche increases offer price for gene sequencing firm Illumina to US$ 51.00 per share...